Русский
Diagnosis of anemic syndrome in patients with active rheumatoid arthritis
DOI: https://dx.doi.org/10.18565/therapy.2024.1.8-15
Semashko A.S., Galushko E.A., Lila A.M.
1) V.A. Nasonova Research Institute of Rheumatology, Moscow; 2) Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow
The aim: to develop an algorithm using hepcidin for the differential diagnosis of chronic inflammation anemia (ACI) from true iron deficiency anemia (IDA) in patients with active rheumatoid arthritis (RA).
Material and methods. The study was prospective. 78 RA patients with high activity of the inflammatory process according to DAS28-ESR were included in the analysis. Patients were recruited sequentially upon admission to hospitalization at V.A. Nasonova Research Institute of Rheumatology. Criterion for anemia was considered to be a decrease in hemoglobin levels below 120 g/l for female and below 130 g/l for male patients. Depending on hemoglobin level, participants were divided into the main (with anemia, n = 47) and control (without anemia, n = 29) groups. All patients had an assessment of DAS28 index, estimation of clinical and biochemical blood parameters (serum iron, total iron-binding serum capacity, hepcidin, interleukin 6).
Results. Among patients with active RA and anemia (n = 47), isolated ACI was diagnosed in 57.4% of cases (n = 27). Classic IDA was diagnosed in 20 patients (42.6%). Significantly higher hepcidin values (120.3 ± 56.71 pg/ml) were determined in patients with ACI comparatively to the control group (90.4 ± 36.9 pg/ml) and RA patients with IDA. Correlation between hepcidin level and interleukin 6 level (rIL-6 = 0.81) was obtained only in the subgroup with ACI. In patients with IDA and without anemia, such kind of correlation was not found. Based on the obtained data, an algorithm for diagnosing anemia in patients with active RA was developed.
Conclusion. The level of hepcidin is an informative indicator for differential diagnosis of the type of anemia during active inflammation. In RA patients with ACI, the highest values of hepcidin in blood serum are detected, while in IDA cases they are staying below the reference values. The study also demonstrates the importance of hepcidin – interleukin 6 correlation.
Literature
1. Насонов Е.Л., Олюнин Ю.А., Лила А.М. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018; 56(3): 263–271. (Nasonov E.L., Olyunin Yu.A., Lila A.M. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018; 56(3): 263–271 (In Russ.)). https://doi.org/10.14412/1995-4484-2018-263-271. EDN: XWRASD. 2. Busby A.D., Wason J., Pratt A.G. et al. The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data. Rheumatology (Oxford). 2022; 61(11): 4297–304. https://doi.org/10.1093/rheumatology/keac139. PMID: 35258566. PMCID: PMC9629371. 3. Radner H. How to improve care for patients with RA and comorbidities. Nat Rev Rheumatol. 2020; 16(11): 607–8. https://doi.org/10.1038/s41584-020-00504-y. PMID: 32908247. 4. Weiss G., Ganz T., Goodnough L.T. Anemia of inflammation. Blood. 2019; 133(1): 40–50. https://doi.org/10.1182/blood-2018-06-856500. PMID: 30401705. PMCID: PMC6536698. 5. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015; 372(19): 1832–43. https://doi.org/10.1056/NEJMra1401038. PMID: 25946282. 6. Petzer V., Theurl I., Weiss G. Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases. Pharmaceuticals (Basel) 2018; 11(4): 135. https://doi.org/10.3390/ph11040135. PMID: 30544952. PMCID: PMC6315795. 7. Мазуров В.И., Лила А.М. Особенности анемического синдрома у больных ревматоидным артритом и системной красной волчанкой. Медицинский академический журнал. 2001; 1(1): 58. (Mazurov V.I., Lila A.M. Features of anemic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. Meditsinskiy akademicheskiy zhurnal = Medical Academic Journal. 2001; 1(1): 58 (In Russ.)). 8. Галушко Е.А., Беленький Д.А. Современные аспекты диагностики и лечения анемии у больных ревматоидным артритом. Научно-практическая ревматология. 2012; 50(5): 98–105. (Galushko E.A., Belenkiy D.A. Modern aspects of diagnosis and treatment of anemia in rheumatoid arthritis patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012; 50(5): 98–105 (In Russ.)). https://doi.org/10.14412/1995-4484-2012-1189. EDN: PMLQQT. 9. Cappellini M.D., Comin-Colet J., de Francisco A. et al.; IRON CORE Group. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017; 92(10): 1068–78. https://doi.org/10.1002/ajh.24820. PMID: 28612425. PMCID: PMC5599965. 10. Лила А.М., Галушко Е.А., Семашко А.С. Патофизиология метаболизма железа и гепсидин: перспективы изучения в ревматологии. Научно-практическая ревматология. 2022; 60(5): 519–525. (Lila A.M., Galushko E.A., Semashko A.S. Pathophysiology of iron and hepcidin metabolism: Research perspectives in rheumatology. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2022; 60(5): 519–525 (In Russ.)). https://doi.org/10.47360/1995-4484-2022-519-525. EDN: DHGFAR. 11. Goodnough L.T., Comin-Colet J., Leal-Noval S. et al. Management of anemia in patients with congestive heart failure. Am J Hematol. 2017; 92(1): 88–93. https://doi.org/10.1002/ajh.24595. PMID: 27779769. 12. Stauder R., Valent P., Theurl I. Anemia at older age: Etiologies, clinical implications, and management. Blood. 2018; 131(5): 505–14. https://doi.org/10.1182/blood-2017-07-746446. PMID: 29141943. 13. Repping-Wuts H., van Riel P., van Achterberg T. Fatigue in patients with rheumatoid arthritis: What is known and what is needed. Rheumatology (Oxford). 2009; 48(3): 207–9. https://doi.org/10.1093/rheumatology/ken399. PMID: 18927188. 14. Gutschow P., Han H., Olbina G. et al. Clinical immunoassay for human hepcidin predicts iron deficiency in first-time blood donors. J Appl Lab Med. 2020; 5(5): 943–53. https://doi.org/10.1093/jalm/jfaa038. PMID: 32674118. PMCID: PMC7497288. 15. Armitage A.E., Drakesmith H. The diagnostic potential of the iron-regulatory hormone hepcidin. HemaSphere. 2019; 3(Suppl): 100–3. https://doi.org/10.1097/HS9.0000000000000236. PMID: 35309797. PMCID: PMC8925696. 16. Lasocki S., Lefebvre T., Mayeur C. et al.; FROG-ICU study group. Iron deficiency diagnosed using hepcidin on critical care discharge is an independent risk factor for death and poor quality of life at one year: An observational prospective study on 1161 patients. Crit Care. 2018; 22(1): 314. https://doi.org/10.1186/s13054-018-2253-0. PMID: 30463596. PMCID: PMC6249884. 17. Cavezzi A., Menicagli R., Troiani E., Corrao S. COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: A possible unifying hypothesis. F1000Res. 2022; 11: 102. https://doi.org/10.12688/ f1000research.108667.2. PMID: 35340277. PMCID: PMC8921693. 18. Rauf A., Shariati M.A., Khalil A.A. et al. Hepcidin, an overview of biochemical and clinical properties. Steroids. 2020; 160: 108661. https://doi.org/10.1016/j.steroids.2020.108661. PMID: 32450084. 19. Wunderer F., Traeger L., Sigurslid H.H. et al. The role of hepcidin and iron homeostasis in atherosclerosis. Pharmacol Res. 2020; 153: 104664. https://doi.org/10.1016/j.phrs.2020.104664. PMID: 31991168. PMCID: PMC7066581. 20. Muckenthaler M.U., Rivella S., Hentze M.W., Galy B. A red carpet for iron metabolism. Cell. 2017; 168(3): 344–61. https://doi.org/10.1016/j.cell.2016.12.034. PMID: 28129536. PMCID: PMC5706455. 21. Yuan J., Zou X.R., Han S.P. et al.; C-STRIDE study group. Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol. 2017; 18(1): 23. https://doi.org/10.1186/s12882-017-0441-9. PMID: 28088175. PMCID: PMC5237491. 22. Marti-Carvajal A.J., Agreda-Perez L.H., Sola I. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 2013(2): CD000332. https://doi.org/10.1002/14651858.CD000332.pub3. PMID: 23450527. PMCID: PMC7032682.
About the Autors
Anna S. Semashko, 3rd year graduate student of V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34a Kashirskoe Highway.
E-mail: annsemashko@gmail.com
ORCID: https://orcid.org/0000-0002-2692-7942
Elena A. Galushko, MD, Dr. Sci. (Medicine), leading researcher at the Department of the evolution of rheumatoid arthritis, V.A. Nasonova Research Institute of Rheumatology. Address: 115522, Moscow, 34 Kashirskoe Highway.
E-mail: egalushko@mail.ru
ORCID: https://orcid.org/0000-0002-2776-4276
Alexander M. Lila, MD., Dr. Sci. (Medicine), professor, corresponding member of RAS, director of V.A. Nasonova Research Institute of Rheumatology, head of the Department of rheumatology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Honored Doctor of the Russian Federation. Address: 115522, Moscow, 34a Kashirskoe Highway.
E-mail: amlila@mail.ru
ORCID: https://orcid.org/0000-0002-6068-3080
Similar Articles
